Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trader I believe ASTRA have first right of refusal to match any offer.
That's inaccurate. Adxs has way more money than 80 mill almost double that
One would think the EU partner would come in the first half of 2017 prior to filing foe EU approval.
Trader ADXS is applying for EU approval this year. If granted share price should increase nicely. IMO
Looks like a wrap for 2016. We can all agree to give a big F U to the stock price this year hoping for a monster 2017. Peace
More cash than that. We raised almost 100 mill since august. It's around 175 mill. I believe
I hear ya. This is pathetic. Company valued around 100 million less cash. 2017 better bring better results
HD. What do you see happening early next year? I see more of the same but will ride it out. The only thing that going to move the SP IMO is a large non dilutive deal, which could happen anytime. I'm just wondering why there hasn't been a deal for AXAL?? It should be very appealing for any large BP and if preclinical scan go for upwards of 1.5 bill. This should be worth 2
Gold. Pretty much all the trials are paid for, so the cash should last a good while. I do agree that his strategy is not working from a value standpoint. The trial results have been very strong as we know. I for one would welcome the sale at this point. I think it's a fair price as we've seen pre-clinical sell for over 1.5 bill. If not that sell AXAL at the very least.
Nope. Hold bout 23k warrants. I was in about 7 years ago and dumped it and jumped back in after Pearson article which looked like a whole lot of BS. Should've sold two summers ago like everyone and bought back In, but oh well I'm gonna ride with Adxs. Not happy at all with share price and see both sides of the company but all your posts are implying something negative.
You just discussed the trial cost as being expensive b/c it's being drawn out. If I'm not mistaken I believe GOG is picking up the cost or most of it anyway.
That's what I thought about the combo data....
In addition to the amount of options he granted himself (about 50% of his current share holdings)you'd think a deal was imminent. I know the options were approved by the board/ compensation committee but Dan controls the board.
Gotcha. Just curious.
What is your theory on What it will take to move share price?
I'm following the big money. That being said, I'm also a little disappointed in the combo data or lack there of. Wasn't much new presented. I'll stick to my belief that the price won't move until we have a substantial AXAL partnership. So it is surprising that a deal hasn't been done yet since they're going after EU approval in 2017. We don't have a sales force so ASTRA for example would want to hit the ground running if/when approval is granted - assuming they're the top candidate for partnership. So the question- who's playing hardball(us or them).
Private placement. (Auto correct)
Actually it was a 2.2 million share p,a cement with FMR taking 1.3 mill. Morningstar shows an increase in tute holding. Nice soft bash though
JUNO took in the azz. It's going to bring down bio today. Jesus
That was me. I actually found his reply:
Hans Vitzthum (LifeSci Advisors) <hans@lifesciadvisors.com>
HI John,
Indeed Ranya Dajani's appointment to the BD team at ADXS is actually a reflection of the company's recognition that, given the volume of opportunities that were being put in front of them, they needed more human capital to assess, qualify and negotiate them. She is joining the company well after the starting bell has rung and has been brought on as another able body.
As you may appreciate, business development is a fickle mistress and timelines are subject to constant change. I think that the best way to think about partnership activity at ADXS is that there is significant activity taking place beneath the waterline. Naturally, the company will make public proclamations when management has finalized a transaction that makes sense for the company and its stakeholders. Unfortunately, the timing of such events are difficult to handicap.
Best,
Hans
Hans C. Vitzthum
I'm shocked that adxs isn't getting heat from big shareholders about his strategy. The science is moving along in the right direction but going it alone doesn't garner any faith from wall street. People keep saying its going to increase our leverage but at what point do you alienate / piss off BP where they move on. Merck has a ton of combo trials I believe I read somewhere. I hope he isn't over playing his hand.
I spoke to IR awhile back when they hired the lady to handle partnerships and Hans indicated they needed her to handle all the requests to partner with ADXS. This leads me to believe ADXS is the ones holding out. My 2 cents
Seems like Dan is going around and presenting the same "state of the company" speech. Frustrating to say the least..
That was a big chunk of that $13.50 private placement..
Very true. If that's the path they take let's all settle in for at least mid next year for EU approval increased value I presume.
I hope the IBB continues its trend upwards which should bring us along as well. Other than substantial deal, I find it hard to see anything else that will move the needle
There was a zero chance of news next week. The reception was the perfect setting and yet it appears the reception was a waste of $$ that could be better well spent.
True but being we have no distribution arm(sales force) so a deal is most likely the avenue to pursue- especially to increase the share price. This platform is valued at crap if u remove the cash. I for one believe that's why there is a huge disconnect between us and ADRO
It's always tomorrow with these guys. I'm annoyed that had a reception. For what? Ink a deal already in the age where deals are being handed out like candy for preclinicals. These clowns can't get a substantial deal done with good data.
My question is, what's the party for? These guys pat themselves on The back more than any team I've come across.
Adage would have to declare within a few days if they added more shares due to the size of their stake in the company I believe. So that didn't double their stake or even add a share for that matter.
I concur. I'm a little surprised the stock didn't get pounded. Let's hope there is more to come.
I'm a little cautious reading into reception. They have done this before at ASCO I believe have a reception that is and pps didn't move much. Hope I'm wrong because I believe fair value is at least 1.5 bill. I would like to see a deal with Astra or whomever disclosed on the 10th as well.
30% above 8 dollar current share price is $10.40 per share
That gets us to 11 bucks. That isn't acceptable with this platform. A non-dilutive deal with BP needs to be done before this stock moves. I'm talking a couple hundred million upfront at least. There is no reason to add shares to the mix, especially if we're looking at EU approval in 2017. We all know we don't have a sales force so a deal must be made. Obviously Astra makes the most sense. The question is who is being unreasonable - advaxis or BP?
I hear ya. Put us out of our misery.
agreed.. Although the science is very good. Dan and Co. have created zero value. IMO we need a 1.5 billon dollar deal with BP or approval. It seems like shorts couldn't care less about upcoming SITC.
Hans@lifesciadvisors.com
Hans Vitzthum
Has anyone heard from Hans the IR guy? I emailed him a couple of times this week and haven't received a reply email. he usually gets back ASAP. I'm wondering if he was told to be radio silent.
At this point would great combo results even get us back to $16, that we achieved after Amgen deal. IMO only a large deal with Astra - talking 1.5 billion plus will get us where we want to go. Otherwise we may have to wait for EU approval next year. This is absurd....
No. it's referring to last years hold. Also, I think they're trying to mislead the ADRO hold as an ADXS hold. Complete BS. barely discusses excellent results.